6626-89-7

Basic information

• Product Name: Benzamide, 5-chloro-2-hydroxy-N- (2-hydroxyethyl)-
• Synonyms: Benzamide, 5-chloro-2-hydroxy-N- (2-hydroxyethyl)-
• CAS NO: 6626-89-7
• Molecular Formula: C₉H₁₀ClNO₃
• Molecular Weight: 215.6336
• Mol File: 6626-89-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 409.2°C at 760 mmHg
• Flash Point: 201.3°C
• Appearance: /
• Density: 1.398g/cm³
• Vapor Pressure: 1.98E-07mmHg at 25°C
• Refractive Index: 1.601
• CAS DataBase Reference: Benzamide, 5-chloro-2-hydroxy-N- (2-hydroxyethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 5-chloro-2-hydroxy-N- (2-hydroxyethyl)-(6626-89-7)
• EPA Substance Registry System: Benzamide, 5-chloro-2-hydroxy-N- (2-hydroxyethyl)-(6626-89-7)

Safety Data

• Hazardous Substances Data: 6626-89-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10ClNO3/c10-6-1-2-8(13)7(5-6)9(14)11-3-4-12/h1-2,5,12-13H,3-4H2,(H,11,14)

Upstream product

• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 
• 141-43-5 ethanolamine 

Relevant articles and documents

New Antianginal Nitro Esters with Reduced Hypotensive Activity. Synthesis and Pharmacological Evaluation of 3--2H-1,3-benzoxazin-4(3H)-ones

New nitro ester 3--2H-1,3-benzoxazin-4(3H)-ones show marked inhibitory activity against ischemia-induced electrocardiographic changes, with only limited systemic hemodynamic effects, and are reported in the present study.These new nitro vasodilators are potent inhibitors of the electrocardiographic T-wave and S-T segment elevation induced by intravenous or intracoronary administration of Arg-vasopressin or methacholine in the anesthetized rat.The most active compounds are up to 300- and 600- fold more potent than glyceryl trinitrate or Nicorandil, respectively.These nitro esters relax in a concentration-dependent manner the isolated rabbit aorta, at higher concentrations (2 - 40-fold) than glyceryl trinitrate, and reduce the mean arterial blood pressure at doses 7 - 300-fold higher than those required by glyceryl trinitrate to exert a similar hypotensive effect.Remarkably, these compounds retain their anti-ischemic and hemodynamic profile after oral (po) administration.These new nitro ester derivatives, endowed with a marked antianginal activity, which is not associated with concurrent and pronounced falls in systemic blood pressure, represent the leads of a new class of selective nitrovasodilators having a preferential action on large coronary vessels, which could be clinically relevant in the treatment of coronary artery diseases.